MedTrace Logo

Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)

NCT05191940 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-20

No results posted yet for this study

Summary

This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.

Conditions

  • Pancreas Cancer

Interventions

RADIATION

Particle-therapy using protons or carbon ions

According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).

DIAGNOSTIC_TEST

Blood sampling

Evaluation before treatment-start, after treatment and follow-up period.

DIAGNOSTIC_TEST

Magnetic resonance imaging

For treatment planning as well as for follow-up radiological tumor assessment.

DIAGNOSTIC_TEST

Computertomography

For treatment planning as well as for follow-up radiological tumor assessment.

DIAGNOSTIC_TEST

18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)

For treatment planning as well as for follow-up radiological tumor assessment.

Sponsors & Collaborators

  • EBG MedAustron GmbH

    lead INDUSTRY

Principal Investigators

  • Piero Fossati, M.D. · EBG MedAustron GmbH

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191940 on ClinicalTrials.gov